Genprex Inc gets green light for continuation of dose escalation Phase 1 of Acclaim-1 Phase 1/2 clinical trial of REQORSA
Genprex, Inc. (NASDAQ:GNPX) has announced that the Safety Review Committee (SRC) has approved continuation to the third and final cohort in the dose...